This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:



Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021

Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021
Seroprevalence of EV-A71 neutralizing antibodies in different age groups in Guangzhou City, China from 2019 to 2021. Abbreviation: EV, enterovirus. Credit: Biosafety and Health (2023). DOI: 10.1016/j.bsheal.2023.05.002

Enterovirus A71 (EV-A71) is a significant hand-foot-mouth disease (HFMD) etiology. The inactivated EV-A71 vaccines were approved in China in 2016. However, the seroprevalence of EV-A71 after the vaccine application and its potential association with the EV-A71 epidemic in the population have been rarely studied.

The authors of an article published in Biosafety and Health analyzed the incidence of EV-A71 and seroepidemiology in Guangzhou City, China. From 2019 to 2021, 167,920 clinically confirmed HFMD cases were reported in Guangzhou. In 6,868 enterovirus-positive samples, Coxsackievirus A6 and Coxsackievirus A16 were dominant genotypes, and only three EV-A71-positive samples were detected, highlighting the deficient activity of EV-A71.

Microneutralization assay was performed on 1,000 representative serum samples. Notably, the seroprevalence and geometric mean titer (GMT) decreased significantly in 2020, and that in the below-three-year age group were increased and even higher than that in three- to five-year age group in 2019 and 2021, which was contrary to the authors' previous surveillance result and other studies in Guangzhou. Furthermore, a moderate decline of GMT level was observed following the vaccination, but the seropositive serums were still detected for 49 months after second immunization, suggesting the long-term persistence of the immunity.

This seroepidemiology study revealed relatively higher neutralizing antibody activity in the susceptible after the EV-A71 was adopted in 2016 in Guangzhou. It may be one of the reasons for the lower epidemic activity of EV-A71 in Guangzhou from 2019 to 2021.

More information: Huimin Lian et al, Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021, Biosafety and Health (2023). DOI: 10.1016/j.bsheal.2023.05.002

Provided by Compuscript Ltd
Citation: Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021 (2023, July 17) retrieved 7 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Learning disabilities in U.S. youth remained steady from 1997 to 2021


Feedback to editors